Kura Oncology Stock Forecast, Price & News

Kura Oncology's stock was trading at $9.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KURA shares have increased by 249.1% and is now trading at $33.69.
View which stocks have been most impacted by COVID-19.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Kura Oncology or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Kura Oncology a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Kura Oncology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Kura Oncology is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Kura Oncology.

Kura Oncology, Inc. (NASDAQ:KURA) issued its quarterly earnings data on Thursday, November, 5th. The company reported ($0.42) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.39) by $0.03.
View Kura Oncology's earnings history.

11 Wall Street analysts have issued 12 month target prices for Kura Oncology's shares. Their forecasts range from $24.00 to $43.00. On average, they anticipate Kura Oncology's share price to reach $34.33 in the next year. This suggests a possible upside of 1.9% from the stock's current price.
View analysts' price targets for Kura Oncology.

Kura Oncology saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 4,330,000 shares, an increase of 25.9% from the October 31st total of 3,440,000 shares. Based on an average daily trading volume, of 724,000 shares, the short-interest ratio is currently 6.0 days.
View Kura Oncology's Short Interest.

Some companies that are related to Kura Oncology include Ultragenyx Pharmaceutical (RARE), Ionis Pharmaceuticals (IONS), Bausch Health Companies (BHC), Arrowhead Pharmaceuticals (ARWR), Perrigo (PRGO), Zai Lab (ZLAB), Amicus Therapeutics (FOLD), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), United Therapeutics (UTHR), Biohaven Pharmaceutical (BHVN), Evotec (EVTCY), Turning Point Therapeutics (TPTX), Allakos (ALLK) and Reata Pharmaceuticals (RETA).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Kura Oncology's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.79%), State Street Corp (3.08%), Victory Capital Management Inc. (3.03%), Boxer Capital LLC (1.85%), Candriam Luxembourg S.C.A. (0.96%) and Polar Capital LLP (0.88%). Company insiders that own Kura Oncology stock include Antonio Gualberto, Ecor1 Capital Fund Qualified,, Kathleen Ford, Marc Grasso and Troy Edward Wilson.
View institutional ownership trends for Kura Oncology.

KURA stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., Victory Capital Management Inc., Sphera Funds Management LTD., Alethea Capital Management LLC, AXA S.A., Squarepoint Ops LLC, State of New Jersey Common Pension Fund D, and J. Goldman & Co LP. Company insiders that have sold Kura Oncology company stock in the last year include Kathleen Ford, Marc Grasso, and Troy Edward Wilson.
View insider buying and selling activity for Kura Oncology.

KURA stock was bought by a variety of institutional investors in the last quarter, including Polar Capital LLP, Polar Capital LLP, Assenagon Asset Management S.A., Candriam Luxembourg S.C.A., Federated Hermes Inc., Boxer Capital LLC, DekaBank Deutsche Girozentrale, and Voloridge Investment Management LLC.
View insider buying and selling activity for Kura Oncology.

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of KURA stock can currently be purchased for approximately $33.69.

Kura Oncology has a market capitalization of $1.91 billion. The company earns $-63,140,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis. Kura Oncology employs 71 workers across the globe.

The official website for Kura Oncology is www.kuraoncology.com.

Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The company can be reached via phone at 858-500-8800 or via email at [email protected]